How do institutional investors view Bdsx currently?

Institutional investors have shown varied views on Biodesix (BDSX). Here's an analysis based on recent data:

1. **Recent Institutional Activity**:
- Several institutional investors have adjusted their stakes in BDSX. For example, Balyasny Asset Management L.P. purchased a new position in the fourth quarter worth approximately $29,000.
- Barclays PLC increased its position by 1,140.5% in the third quarter, now owning 23,036 shares worth $41,000.
- Boothbay Fund Management LLC acquired a new stake in the fourth quarter valued at $52,000.
- MYDA Advisors LLC purchased a new stake in the fourth quarter worth $76,000.
- Cubist Systematic Strategies LLC lifted its holdings by 385.9% in the fourth quarter, now owning 51,024 shares valued at $78,000.
2. **Institutional Ownership**: Institutional investors currently own 20.96% of BDSX's stock. This indicates a significant presence of institutional investment, but not a majority stake.
3. **Analyst Ratings and Targets**:
- Analysts have set a consensus price target of $1.75 for BDSX, which is above the current trading price of $0.36. This suggests that analysts believe the stock has potential for growth from its current level.
- Scotiabank has lowered its price target from $3 to $2, which reflects a more cautious stance on the stock. This adjustment could influence the views of institutional investors who rely on analyst recommendations and price targets.
4. **Short Interest**: Short interest in BDSX increased by 29.5% in March, totaling 1,260,000 shares as of March 15, 2025. This increase in short interest could indicate that some investors are cautious or bearish on the stock in the near term.
5. **Financial Performance**: Biodesix reported a quarterly revenue of $20.4 million, surpassing the forecasted $19.87 million. The company also posted an EPS of -$0.06, slightly better than the anticipated -$0.07. These results reflect a strong revenue growth, although the negative EPS could be a concern for some investors.

In conclusion, institutional investors have shown interest in BDSX, with some recent purchases and adjustments to their stakes. However, the mixed analyst ratings, including a lowered price target by Scotiabank, and the increase in short interest suggest that institutional views on BDSX are not unanimous. Investors should consider these factors when assessing the institutional perspective on Biodesix.